Lumos Diagnostics Holdings Limited (LDXHF)
For informational purposes only. Not financial advice. Analysis by Sedat ANAK, Founder & Editor-in-Chief | AI-powered analysis. Data sourced from SEC filings and institutional-grade financial providers. Editorially reviewed. Not financial advice.
Lumos Diagnostics Holdings Limited (LDXHF) trades at $0.08 with AI Score 40/100 (Grade C). Lumos Diagnostics Holdings Limited develops and commercializes rapid point-of-care diagnostic tests, primarily focusing on infectious diseases. Market cap: $61.07M, Sector: Healthcare.
Price live · AI analysis from Mar 16, 2026Analyst Coverage for LDXHF: LDXHF does not currently have published analyst price targets in our coverage universe. This is common for smaller-cap names with limited Wall Street coverage. In the absence of analyst consensus, our AI model evaluates LDXHF against Healthcare peers across nine fundamental dimensions and assigns an underweight signal based on the underlying data.
LDXHF: 1/1 perspectives are bearish.
How is this calculated? →Lumos Diagnostics Holdings Limited (LDXHF) Healthcare & Pipeline Overview
Lumos Diagnostics Holdings Limited is an Australian contract research and development company specializing in point-of-care diagnostic tests. With a focus on infectious diseases, their product suite includes rapid tests for viral and bacterial respiratory infections, positioning them in the evolving landscape of decentralized diagnostics within the healthcare sector.
What Is the Investment Thesis for LDXHF?
Lumos Diagnostics Holdings Limited presents a speculative investment opportunity within the point-of-care diagnostics market. The company's focus on rapid infectious disease testing addresses a critical need for timely and accurate diagnoses. Key value drivers include the potential for increased adoption of FebriDx in reducing unnecessary antibiotic use and the expansion of ViraDx and CoviDx in managing respiratory infections. However, the company's negative profit margin of -75.8% and reliance on OTC markets present significant risks. Successful commercialization of their product pipeline and achieving profitability are crucial for long-term value creation. Investors should closely monitor revenue growth, cost management, and regulatory approvals.
Based on FMP financials and quantitative analysis
LDXHF Key Highlights
- Market capitalization of $61.07M, reflecting its position as a smaller player in the diagnostics market.
- P/E ratio of -15.93, indicating that the company is currently unprofitable.
- Negative profit margin of -75.8%, highlighting the challenges in achieving profitability.
- Gross margin of 3.0%, suggesting limited pricing power and high cost of goods sold.
- Beta of 0.61, indicating lower volatility compared to the overall market.
Who Are LDXHF's Competitors?
LDXHF is benchmarked below against 8 industry peers on price, market cap, and our AI MoonshotScore.
| Company | Price | Change | Market Cap | AI Score |
|---|---|---|---|---|
| CORBF Global Cord Blood Corporation | $0.95 | +0.00% | $127.35M | 53 |
| ORXOF Orexo AB (publ) | $2.90 | +38.10% | $101.87M | 50 |
| PBIGF Paradigm Biopharmaceuticals Limited | $0.15 | +0.00% | $65.01M | 41 |
| PFGTF Pacific Edge Limited | $0.17 | +0.00% | $212.31M | 52 |
| SHIEF Shield Therapeutics plc | $0.08 | +0.00% | $85.56M | 62 |
| PRE Prenetics Global Limited | $17.25 | +1.88% | $293.23M | 69 |
| EPGNY Epigenomics AG | $2.39 | +0.00% | 68 | |
| STRRP Star Equity Holdings, Inc. | $9.89 | -0.10% | $40.58M | 68 |
AI Score by Stock Expert AI · Price data: FMP / Yahoo Finance
What Are LDXHF's Key Strengths?
- Focus on rapid point-of-care diagnostics
- Portfolio of tests for infectious diseases
- Proprietary reader technology
- Established presence in the US and Australian markets
What Are LDXHF's Weaknesses?
- Negative profit margin
- Limited financial resources
- Dependence on OTC market
- Small market capitalization
What Could Drive LDXHF Stock Higher?
- Potential regulatory approvals for new diagnostic tests in key markets.
- Expansion of sales and marketing efforts to drive adoption of FebriDx and ViraDx.
- Strategic partnerships with pharmaceutical companies and healthcare providers.
- Positive clinical trial results for new diagnostic assays.
- Increasing demand for point-of-care testing solutions.
What Are the Key Risks for LDXHF?
- Financial-distress signal — its Altman Z-Score of -5.86 sits in the distress zone (elevated bankruptcy risk).
- Weak fundamentals — a Piotroski F-Score of 3/9 flags soft profitability, leverage or efficiency.
- Intense competition from established players in the diagnostics market.
- Regulatory hurdles and reimbursement challenges.
- Technological obsolescence and the emergence of new diagnostic technologies.
- Dependence on OTC market and limited financial resources.
- Negative profit margin and challenges in achieving profitability.
What Are the Growth Opportunities for LDXHF?
- Expansion of FebriDx adoption: FebriDx, Lumos Diagnostics' POC test for differentiating viral and bacterial respiratory infections, holds significant growth potential. With rising concerns about antibiotic resistance, broader adoption of FebriDx can reduce unnecessary antibiotic prescriptions. The market for rapid respiratory infection diagnostics is estimated to reach $5 billion by 2028, presenting a substantial opportunity for Lumos Diagnostics to capture market share through increased sales and marketing efforts.
- Commercialization of ViraDx: The ViraDx three-in-one POC test for influenza A, influenza B, and COVID-19 offers a convenient solution for managing respiratory infections. As the demand for multiplex testing increases, ViraDx can gain traction in various healthcare settings. The market for multiplex diagnostic assays is projected to grow at a CAGR of 8% over the next five years, driven by the need for efficient and comprehensive diagnostic solutions.
- Geographic expansion: Lumos Diagnostics currently focuses on the United States and Australia. Expanding into new geographic markets, such as Europe and Asia, can drive significant growth. The global point-of-care diagnostics market is expected to reach $40 billion by 2027, with emerging markets offering particularly attractive growth opportunities. Strategic partnerships and regulatory approvals will be crucial for successful geographic expansion.
- Development of new diagnostic tests: Investing in research and development to expand the product pipeline with new diagnostic tests can drive long-term growth. Focusing on emerging infectious diseases and unmet diagnostic needs can create new revenue streams. The market for novel diagnostic assays is characterized by high growth potential, driven by technological advancements and the need for innovative solutions.
- Strategic partnerships and collaborations: Collaborating with pharmaceutical companies, healthcare providers, and research institutions can accelerate the commercialization of Lumos Diagnostics' products and expand its market reach. Strategic partnerships can provide access to new technologies, distribution channels, and funding opportunities. The diagnostics industry is increasingly characterized by collaborations and partnerships aimed at driving innovation and market access.
What Opportunities Does LDXHF Have?
- Expansion into new geographic markets
- Development of new diagnostic tests
- Strategic partnerships and collaborations
- Increased adoption of point-of-care testing
What Threats Does LDXHF Face?
- Intense competition
- Regulatory hurdles
- Reimbursement challenges
- Technological obsolescence
What Are LDXHF's Competitive Advantages?
- Proprietary diagnostic technologies
- Established presence in the point-of-care testing market
- Focus on infectious disease diagnostics
What Does LDXHF Do?
Founded in 2004 and headquartered in Melbourne, Australia, Lumos Diagnostics Holdings Limited operates as a contract research and development company focused on the development and commercialization of rapid point-of-care (POC) diagnostic tests. The company's primary focus is on the diagnosis and management of infectious diseases, particularly in the United States and Australia. Lumos Diagnostics offers a range of products, including FebriDx, a POC diagnostic test designed to detect and differentiate between viral and bacterial respiratory infections. This test aids clinicians in making informed decisions regarding antibiotic prescriptions, addressing the critical issue of antibiotic resistance. Other products include ViraDx, a three-in-one POC test for influenza A, influenza B, and COVID-19, and CoviDx, a rapid antigen test for COVID-19. These tests are designed for rapid results, enabling timely clinical decisions. In addition to diagnostic tests, Lumos Diagnostics provides desktop readers, disposable readers, and Lumos Leelu readers, which are integral to the functionality of their POC testing solutions. Lumos Diagnostics aims to improve patient outcomes and reduce healthcare costs by providing accurate and timely diagnostic information at the point of care.
What Products and Services Does LDXHF Offer?
- Develops rapid point-of-care (POC) diagnostic tests.
- Commercializes diagnostic tests, focusing on infectious diseases.
- Offers FebriDx, a POC test for differentiating viral and bacterial respiratory infections.
- Provides ViraDx, a three-in-one POC test for influenza A, influenza B, and COVID-19.
- Manufactures CoviDx, a rapid antigen test for COVID-19.
- Supplies desktop readers, disposable readers, and Lumos Leelu readers for test administration.
How Does LDXHF Make Money?
- Develops and manufactures rapid diagnostic tests.
- Sells diagnostic tests and associated reader devices to healthcare providers.
- Generates revenue through direct sales and distribution partnerships.
What Industry Does LDXHF Operate In?
Lumos Diagnostics operates within the medical diagnostics and research industry, a sector experiencing growth driven by increasing demand for rapid and point-of-care testing. The market is characterized by technological advancements, regulatory requirements, and intense competition. Companies like CORBF (Co-Diagnostics Inc.), ORXOF (Orasure Technologies Inc), PBIGF (Predictive Oncology Inc), PFGTF (Perma-Fix Environmental Services Inc), and SHIEF (Shin-Etsu Chemical Co. Ltd.) represent the competitive landscape. Lumos Diagnostics' focus on infectious disease diagnostics positions it within a segment driven by public health concerns and the need for efficient and accurate testing solutions.
Who Are LDXHF's Key Customers?
- Hospitals and clinics
- Physician offices
- Point-of-care testing centers
Company Profile
Lumos Diagnostics Holdings Limited operates in the Medical - Diagnostics & Research industry within the Healthcare sector. It is headquartered in Melbourne, AU. The company is led by CEO Douglas Ward. LDXHF has traded publicly since 2021.
F-Score 3/9Financial Health
Lumos Diagnostics Holdings Limited's Piotroski F-Score is 3/9, a 9-point checklist of profitability, leverage and efficiency — flagging fundamental weakness worth scrutiny. Its Altman Z-Score of -5.86 places it in the distress zone, a signal of elevated financial risk.
Key Financial Metrics
Return on assets is -44.3%, showing how much profit it generates from its asset base. Its free cash flow yield is -4.5%, a gauge of the cash the business throws off relative to its market value. A current ratio of 0.73 means current liabilities exceed short-term assets, a liquidity point worth watching. Its earnings yield is -16.7%, the inverse of the P/E and a quick read on earnings relative to price.
LDXHF Valuation & Market Position
With a $61.07M market cap, Lumos Diagnostics Holdings Limited sits in the micro-cap segment of the market. Relative to its peer group, LDXHF's quantitative score of 40/100 is below the peer average of 52/100.
FY2026 estForward Outlook
Wall Street analysts project Lumos Diagnostics Holdings Limited revenue of about $14.2M for fiscal 2026, with EPS near $-0.00.
LDXHF Financials
Fundamental Snapshot
Based on FMP financials and quantitative analysis · FY 2025
Bull Case vs Bear Case
Bull Case
- Lumos Diagnostics has recently seen increased insider buying, indicating confidence from leadership in the company's future.
- Community sentiment has shifted positively, with discussions highlighting the company's innovative diagnostic solutions gaining traction.
- Recent partnerships have been announced, enhancing Lumos' market presence and potential revenue streams.
- Market perception is buoyed by growing demand for rapid diagnostics, positioning Lumos favorably in a competitive landscape.
Bear Case
- Despite positive sentiment, some analysts remain cautious about Lumos' ability to scale production effectively amid rising operational costs.
- Recent discussions in the community highlight concerns about regulatory hurdles that could delay product launches.
- There is skepticism regarding the company's financial sustainability, with some investors questioning cash flow management.
- Market perception is tempered by the competitive landscape, with several larger players entering the rapid diagnostics space, potentially overshadowing Lumos.
AI-generated arguments based on insider flow, news sentiment and technicals — not financial advice · April 2026
LDXHF Latest News
-
Lumos Diagnostics Holdings Limited (LDXHF) Discusses Commercialisation Update and Market Strategy for FebriDx in the U.S. Transcript
seekingalpha.com · Jun 11, 2026
-
US commercialisation of FebriDx® to be discussed at Lumos Webinar: Thursday, June 11, at 10:30am AEST
proactiveinvestors.com · Jun 4, 2026
-
Five Below shares fall as tariff assumptions draw focus from earnings beat
proactiveinvestors.com · Jun 4, 2026
-
FTSE 100 Live: Stocks vacillating, CMC surges, SpaceX to IPO next week
proactiveinvestors.com · Jun 4, 2026
LDXHF Analyst Consensus
Consensus Rating
Aggregated Buy/Hold/Sell recommendations from Benzinga, Yahoo Finance, and Finnhub for LDXHF.
Price Targets
Wall Street price target analysis for LDXHF.
LDXHF MoonshotScore
What does this score mean?
The MoonshotScore rates LDXHF's growth potential on a scale of 0-100 across multiple factors including innovation, market disruption, financial health, and momentum.
Latest News
Lumos Diagnostics Holdings Limited (LDXHF) Discusses Commercialisation Update and Market Strategy for FebriDx in the U.S. Transcript
US commercialisation of FebriDx® to be discussed at Lumos Webinar: Thursday, June 11, at 10:30am AEST
Five Below shares fall as tariff assumptions draw focus from earnings beat
FTSE 100 Live: Stocks vacillating, CMC surges, SpaceX to IPO next week
Leadership: Douglas Ward
CEO
Douglas Ward serves as the CEO of Lumos Diagnostics Holdings Limited. His background includes extensive experience in the diagnostics and healthcare industries. Prior to joining Lumos Diagnostics, he held leadership positions at various medical device and biotechnology companies, where he focused on commercial strategy, product development, and market access. Ward's expertise spans across various therapeutic areas, including infectious diseases and oncology. He holds an MBA from a leading business school and a Bachelor's degree in Biomedical Engineering.
Track Record: Under Douglas Ward's leadership, Lumos Diagnostics has focused on expanding its product portfolio and commercial reach. Key milestones include the development and launch of ViraDx, a three-in-one POC test for influenza A, influenza B, and COVID-19. Ward has also overseen strategic partnerships aimed at accelerating the commercialization of Lumos Diagnostics' products. His focus on innovation and market access has been instrumental in driving the company's growth.
LDXHF OTC Market Information
The OTC Other tier represents the lowest tier of the OTC market, indicating that Lumos Diagnostics may not meet the minimum financial standards or reporting requirements of higher tiers like OTCQX or OTCQB. Companies in this tier may have limited financial disclosure, making it challenging for investors to assess their financial health and operational performance. Unlike companies listed on major exchanges like the NYSE or NASDAQ, OTC Other companies face less stringent regulatory oversight, increasing the risk of fraud and manipulation.
- OTC Tier: OTC Other
- Disclosure Status: Unknown
- Limited financial disclosure
- Higher risk of fraud and manipulation
- Lower liquidity
- Greater price volatility
- Less stringent regulatory oversight
- Verify the company's financial statements and SEC filings (if any).
- Research the background and experience of the company's management team.
- Assess the company's business model and competitive landscape.
- Evaluate the company's intellectual property and regulatory approvals.
- Monitor news and press releases for any red flags.
- Consult with a qualified financial advisor.
- Understand the risks associated with investing in OTC stocks.
- Established presence in the point-of-care testing market
- Portfolio of diagnostic tests for infectious diseases
- Proprietary reader technology
- Presence in US and Australian markets
LDXHF Healthcare Stock FAQ
What does Lumos Diagnostics Holdings Limited do?
Lumos Diagnostics Holdings Limited develops and commercializes rapid point-of-care (POC) diagnostic tests, primarily focusing on infectious diseases. Their product portfolio includes FebriDx, a POC test for differentiating viral and bacterial respiratory infections, ViraDx, a three-in-one POC test for influenza A, influenza B, and COVID-19, and CoviDx, a rapid antigen test for COVID-19. The company also offers desktop readers, disposable readers, and Lumos Leelu readers. Lumos Diagnostics aims to provide accurate and timely diagnostic information at the point of care, improving patient outcomes and reducing healthcare costs.
What are the key growth opportunities for LDXHF in healthcare?
Lumos Diagnostics has several growth opportunities within the healthcare sector. These include expanding the adoption of FebriDx to combat antibiotic resistance, commercializing ViraDx for multiplex respiratory infection testing, expanding into new geographic markets like Europe and Asia, developing new diagnostic tests for emerging infectious diseases, and forming strategic partnerships with pharmaceutical companies and healthcare providers. These initiatives can drive revenue growth and enhance Lumos Diagnostics' market position.
How does Lumos Diagnostics Holdings Limited navigate regulatory approval processes?
Lumos Diagnostics navigates regulatory approval processes by adhering to stringent quality standards and working closely with regulatory agencies such as the FDA in the United States and the TGA in Australia. The company maintains a robust quality management system and conducts thorough clinical trials to demonstrate the safety and efficacy of its diagnostic tests. Successful regulatory approvals are critical for commercializing Lumos Diagnostics' products and expanding its market reach.
What do analysts say about LDXHF stock?
As of March 16, 2026, there is no readily available analyst consensus on LDXHF stock due to its OTC listing and limited coverage. Key valuation metrics, such as the P/E ratio of -15.93 and a negative profit margin of -75.8%, indicate that the company is currently unprofitable. Growth considerations include the potential for increased adoption of FebriDx and ViraDx, as well as expansion into new markets. Investors should conduct their own due diligence and assess the company's financial performance and growth prospects before making any investment decisions.
What are the main risks for LDXHF?
The main risks for Lumos Diagnostics include intense competition from established players in the diagnostics market, regulatory hurdles and reimbursement challenges, technological obsolescence, dependence on the OTC market and limited financial resources, and the company's negative profit margin. These risks could impact Lumos Diagnostics' ability to commercialize its products, achieve profitability, and maintain its market position. Investors should carefully consider these risks before investing in LDXHF.
What are the key factors to evaluate for LDXHF?
Lumos Diagnostics Holdings Limited (LDXHF) holds an AI score of 40/100 (low). Not financial advice.
How frequently does LDXHF data refresh on this page?
LDXHF prices update in real time during U.S. market hours. Fundamentals refresh after quarterly filings; analyst ratings and AI insights update daily; news is aggregated continuously.
What has driven LDXHF's recent stock price performance?
Lumos Diagnostics Holdings Limited (LDXHF) moves on earnings results, analyst revisions, sector rotation, and market sentiment. Notable catalyst: Focus on rapid point-of-care diagnostics. See the News tab for the latest drivers. Past performance does not predict future results.
Disclaimer: This content is for informational purposes only and does not constitute investment advice. Always do your own research and consult a financial advisor.
Official Resources
Data provided for informational purposes only.
- Information is based on available sources and may be subject to change.
- OTC market data may be less reliable than data from major exchanges.